3[2]Caixia T,Hongwen F,Xiran L.Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo.J Dermatol Sci,1999,21(1):59-62.
4[3]Marsland AM,Griffiths CE.The macrolide immunosuppressants in dermatology:mechanisms of action.Eur J Dermatol,2002,12(6):618-622.
5[4]Lan CC,Chen GS,Chiou MH,et al.FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes:possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.Br J Dermatol,2005,153(3):498-505.
6[5]Grimes PE,Soriano T,Dytoc MT.Topical tacrolimus for repigmentation of vitiligo.J Am Acad Dermatol,2002,47(5):789-791.
7[6]Tanghetti EA.Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo:results of a prospective patient series.Cutis,2003,71(2):158-162.
8[7]Silverberg NB,Lin P,Travis L,et al.Tacrolimus ointment promotes repigmentation of vitiligo in children:a review of 57 cases.J Am Acad Dermatol,2004,51(5):760-766.
9[8]Naylor M,Elmets C,Jaracz E,et al.Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus.J Dermatolog Treat,2005,16(3):149-153.
10[9]Hanifin JM,Paller AS,Eichenfield L,et al.Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.J Am Acad Dermatol 2005,53 Suppl 2:186-194.
